November 2018

Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is currently conducting more than 120 research studies, including clinical trials of targeted therapies and novel immunotherapy approaches.

CAR T-cell trial offers second-line therapy for aggressive lymphoma

Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new clinical trial at Providence Cancer Institute . The study treatment, JCAR017 , provided “a durable reduction or eradication of cancer” in a Phase I study, including complete cancer eradication in just over half of the patients. Read more in Lymphoma News Today .  Read More About This Study

All current open studies:

Brain Cancer Breast Cancer Gastrointestinal Cancers  Genitourinary Cancers Gynecologic Cancers

Head and Neck Cancers Hematologic Cancers Lung Cancer Melanoma Phase 1 Trials

Find additional studies for many types of cancer in Multiple Tumor Types .

New studies are posted frequently - please check our  website  for a complete list of our current studies. For more information, call 503-215-2614.

Refer A Patient

Email Our Team

See All Open Studies

Earle A. Chiles Research Institute

Sign up to receive this newsletter

‌ ‌ ‌